Drug lookup | Fillwise

METHAZOLAMIDE

All products: not a benefit

Other products in the same Health Canada class (S01E, S01EC) — coverage varies; not interchangeable

Acetazolamide (Acetazolamide): general benefit, Not a benefit
Brinzolamide (Azopt): limited Use 171, 172, 387
Brimonidine + brinzolamide (Simbrinza): limited Use 466, 393
Dorzolamide (Trusopt): limited Use 171, 172, 387
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit

11 more in the class list below

Neptazane · DIN 02238071 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.Discontinued 2002-05-17 · checked 2026-09-20

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Neptazane · DIN 02238071 Manufacturer: Wyeth Pharmaceuticals; listing date 1999-12-16 Health Canada: Cancelled post market since 2002-05-17 · brand NEPTAZANE TABLETS 50MG · ATC S01EC05 METHAZOLAMIDE · form Tablet · route Oral · ingredients METHAZOLAMIDE 50 MG · company Wyeth-ayerst canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Neptazane: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61455 · Verify on the e-Formulary ↗ (DIN 02238071)

Source record

DIN 02238071: Neptazane Raw flags: notABenefit=Y, sec3=Y Item: 523600043; group id 633; item number 1602; lccId None; manufacturer id WAY Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238071 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61455

Interchangeable products

Methazolamide · DIN 02245882 · $0.4913

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more

Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS Adjunctive treatment of chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle closure glaucoma, where delay of surgery is desired in order to lower intraocular pressure. https://pdf.hres.ca/dpd_pm/00010564.PDF PM date: not printed or not captured Source product: METHAZOLAMIDE; DIN 02245882; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Neptazane: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026